ARMY AL&T
reducing the size of the system and developed command-and-control software to align with C5ISR Mounted Mission Command. (C5ISR is command, control, communications, computers, cyber, intelligence, surveillance and reconnais- sance.) It also demonstrated platform adaptability by integrating onto a new unmanned ground vehi- cle and an unmanned aerial vehicle, translating all the data from those sensors to usable informa- tion for the Soldier and the chain of command.
Senior leader support for acquisition reform made the rapid pace for this modernization possible. An operational requirement document was used instead of developing a new capabilities develop- ment document, and a modified work order was used to reduce testing requirements and cost and increase the speed of delivery to the warfighter. Modular open system architecture enabled parallel development of the CBRN sensors and the plat- form integration. Using these methods, the Stryker NBCRV SSU program designed and constructed fully integrated prototypes within 100 days from receipt of the validated requirement.
"I am tremendously proud of our team’s ability to successfully design and build fully integrated proto- types in 100 days for the Defense Department’s CBRN mounted reconnaissance capability for manned and unmanned systems. This dedication and commitment enabled us to deliver the first inte- grated prototype three years ahead of schedule." said Lt. Col. Jeffrey Strauss, joint product manager for Reconnaissance and Platform Integration.
Where does JPEO-CBRND fit into
the bigger picture? One of the responsibilities of the JPEO-CBRND is to make medical countermeasure capabilities available to those who need them. As such, the organization has existing capabilities and exper- tise to rapidly respond to COVID-19, particularly in product development, manufacturing, clinical trials
management and fielding. JPEO-CBRND has been engaged in COVID-19 response efforts since the first cases were identified, supporting the Office of the Assistant Secretary of Defense for Health Affairs, which is the designated health lead for DOD’s COVID-19 response.
“The JPEO-CBRND’s diverse portfolio allows us to respond to the COVID-19 pandemic through a comprehensive, three-pronged approach. Coor- dinated efforts to prevent, detect and treat this disease will facilitate the delivery of effective medi- cal countermeasures that protect both warfighters and civilians alike,” said Col. Ryan Eckmeier, joint project manager for Chemical, Biological, Radio- logical and Nuclear Medical.
JPEO-CBRND has accelerated rapid response for DOD and interagency partners to meet objectives in detection, prevention and treatment.
DETECTION AND DIAGNOSTICS
JPEO-CBRND has made great strides in the fight to rapidly identify COVID-19, to prevent further spread of the disease and inform treatment options. The Next Generation Diagnostics System is already fielded to DOD and Centers for Disease Control and Prevention sites worldwide—with newly fielded systems increasing exponentially in response to the joint services’ demand—and is being used for COVID-19 testing.
Using the BioFire Defense LLC’s FilmArray device and associated respiratory panels allowed for identification of some types of coronavirus (such as those that cause SARS, severe acute respira- tory syndrome, and MERS, Middle East respiratory syndrome) and the ruling out of other respiratory diseases presenting with symptoms similar to those of COVID-19.
However, existing BioFire respiratory panels would not recognize COVID-19 specifically. JPEO- CBRND addressed this capability gap by working
https://asc.ar my.mil
109
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172
